Different therapeutic approaches on quality of life in patients with inflammatory bowel disease

Abstract

BackgroundThe chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated.MethodsConsecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment.ResultsMCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease economic burden (P = 0.048).ConclusionsMCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients. Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD.Electronic supplementary materialThe online version of this article (doi:10.1186/s12876-014-0199-5) contains supplementary material, which is available to authorized users.

<p>Health-related quality of life outcomes and economic burden of inflammatory bowel disease in Japan</p>

“…Indeed, new biologic agents, such as adalimumab, were found to improve HRQoL, increase work productivity, and reduce activity impairment 34. Similarly, treatment with infliximab improved HRQoL in Chinese patients with IBD 35. Apart from HRQoL, studies from the US and Spain have shown that usage of new biologic agents, such as infliximab and adalimumab, is associated with a lower HRU 36,37.…”

Manejo integral de la enfermedad inflamatoria intestinal: más allá de una terapia farmacológica adecuada

“…En relación al tratamiento, infliximab, un seguro y efectivo agente biológico para el tratamiento de la EII, ha demostrado mejorar de manera significativa la calidad de vida al compararlo con el grupo tratado con terapia convencional 36 . Esto se podría explicar por la remisión clínica continua y la curación de la mucosa cuando se utiliza esta terapia.…”

“…Sin embargo, la mayoría de las herramientas utilizadas en la actualidad son largas y consumen tiempo, lo que explica su bajo uso en la práctica clí-nica. Los instrumentos clásicos para medir calidad de vida son el SF-36 y el SF-12, los cuales se han utilizado en algunos estudios en EII 32,36,37 , pero no son específicos para esta patología. El instrumento más comúnmente utilizado en la práctica clínica y en los estudios es el IBDQ 31,[32][33][34][35][36]38 desarrollado en la Universidad de McMaster, Ontario, Canadá, el cual consta de 32 preguntas 39 .…”

Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn’s Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany

“…Nevertheless, disease-related hospitalizations and other socioeconomic effects of CD cause high utilization of health-care resources but might be minimized by an adequate treatment strategy [10-13]. So far, the effect of IFX on CD-related hospitalizations and work ability impairment is inconsistently assessed [10, 14, 15]. Usually, studies concerning CD-related hospitalizations focus on hospitalization costs, differences between older and younger CD patients, or compare different CD treatments and their influence on disease-related hospitalization rates [10, 14, 15].…”

“…So far, the effect of IFX on CD-related hospitalizations and work ability impairment is inconsistently assessed [10, 14, 15]. Usually, studies concerning CD-related hospitalizations focus on hospitalization costs, differences between older and younger CD patients, or compare different CD treatments and their influence on disease-related hospitalization rates [10, 14, 15]. However, the extent to which more frequent hospitalizations lead to a worsening of HRQoL has mostly been neglected in previous studies.…”